just who are the 2 geniuses behind iBio's RubrYc:
Post# of 150
(Total Views: 355)
Posted On: 02/19/2023 4:51:29 PM
just who are the 2 geniuses behind iBio's RubrYc:
Dr. Isaac Bright MD - Bio
Dr. Isaac Bright serves as Co-Founder, Chief Executive Officer & Board Member at RubrYc Therapeutics. Mr. Bright served as Vice President, Corporate Development at Synthetic Biologics. He also served as Board Member at ImagineAb. He also served as an Executive at HealthTell. Mr. Isaac Bright served as Partner at Merieux Developpement. He is a Partner on the Merieux Developpement management team and started his career as Market Development Associate for Pacific Consultants. Concomitant with completing his medical training, Isaac was a successful investment banking analyst in the biotechnology group at CIBC World Markets. He was a Howard E. Mitchell Fellow at the Wharton School from 2004-2006, after which Isaac served as Corporate Development Associate and Director of Business Development for Medtronic from 2006 to 2009. In 2009, Isaac joined QuantaLife as VP Corporate Development & Molecular Diagnostics until its successful trade sale to Bio-Rad Laboratories in 2011. Isaac earned his Bachelor's degree in Biochemistry from Pepperdine University, his MD at the Stanford University School of Medicine, and his MBA from The Wharton School at the University of Pennsylvania.
Dr. Matthew P Greving - Bio
Dr. Greving has a passion and an awarded record for innovation in computation and laboratory integration. At RubrYc, he leads development of a unique machine learning backed epitope-selective antibody discovery platform for challenging targets. Dr. Greving founded his first company 20 years ago that developed software to deliver legacy mainframe data and algorithms to modern systems. Dr. Greving received a Ph.D. in Biochemistry in 2010. His thesis research helped establish the “Immunosignature” technology. Dr. Greving completed his metabolomics post-doctoral research at Scripps Research. Subsequently, Dr. Greving founded Nextval that developed a high-throughput mass spectrometry screening technology. These developments resulted in two prestigious awards: Society for Lab Automation and Screening (SLAS) 2012 “Innovation of the Year”, and R&D Magazine’s 2013 “Oscar of Innovation”. After Nextval, Dr. Greving joined HealthTell to commercialize the Immunosignature diagnostic. He then integrated HealthTell’s library platform with molecular simulation and machine learning to build RubrYc’s discovery platform.
$3 to $5 at capital raise | $9 by Aug.
nuff said...!
MOO puff
Dr. Isaac Bright MD - Bio
Dr. Isaac Bright serves as Co-Founder, Chief Executive Officer & Board Member at RubrYc Therapeutics. Mr. Bright served as Vice President, Corporate Development at Synthetic Biologics. He also served as Board Member at ImagineAb. He also served as an Executive at HealthTell. Mr. Isaac Bright served as Partner at Merieux Developpement. He is a Partner on the Merieux Developpement management team and started his career as Market Development Associate for Pacific Consultants. Concomitant with completing his medical training, Isaac was a successful investment banking analyst in the biotechnology group at CIBC World Markets. He was a Howard E. Mitchell Fellow at the Wharton School from 2004-2006, after which Isaac served as Corporate Development Associate and Director of Business Development for Medtronic from 2006 to 2009. In 2009, Isaac joined QuantaLife as VP Corporate Development & Molecular Diagnostics until its successful trade sale to Bio-Rad Laboratories in 2011. Isaac earned his Bachelor's degree in Biochemistry from Pepperdine University, his MD at the Stanford University School of Medicine, and his MBA from The Wharton School at the University of Pennsylvania.
Dr. Matthew P Greving - Bio
Dr. Greving has a passion and an awarded record for innovation in computation and laboratory integration. At RubrYc, he leads development of a unique machine learning backed epitope-selective antibody discovery platform for challenging targets. Dr. Greving founded his first company 20 years ago that developed software to deliver legacy mainframe data and algorithms to modern systems. Dr. Greving received a Ph.D. in Biochemistry in 2010. His thesis research helped establish the “Immunosignature” technology. Dr. Greving completed his metabolomics post-doctoral research at Scripps Research. Subsequently, Dr. Greving founded Nextval that developed a high-throughput mass spectrometry screening technology. These developments resulted in two prestigious awards: Society for Lab Automation and Screening (SLAS) 2012 “Innovation of the Year”, and R&D Magazine’s 2013 “Oscar of Innovation”. After Nextval, Dr. Greving joined HealthTell to commercialize the Immunosignature diagnostic. He then integrated HealthTell’s library platform with molecular simulation and machine learning to build RubrYc’s discovery platform.
$3 to $5 at capital raise | $9 by Aug.
nuff said...!
MOO puff
(0)
(0)Ibio (IBIO) Stock Research Links
Scroll down for more posts ▼